Roche Spin-Off Nimble Therapeutics to Commercialize its Drug Development Technology
Shots:
- Nimble Therapeutics spins out from Roche to commercialize its chemical synthesis drug discovery & development technology and has received $10M Series A funding from Telegraph Hill Partners
- The focus of spinning out Nimble Therapeutics is to expand Roche’s chemical synthesis technology by collaborating with other pharma companies to jointly develop drug candidates for multiple therapeutic areas
- The chemical synthesis technology harnesses the power of photolithography and an extensive library of photoprotected amino acids for synthesis & screening of peptides including scaffolded natural and modified macrocyclic peptidomimetics
Ref: Nimble Therapeutics | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com